Impact

Created in 2002 by the Fund’s Partners, a group of UK public sector research establishments led by STFC, BBSRC, NERC and Dstl, the Fund’s primary objective is to commercialise high quality science. We help establish technology companies that stem out of research by investing in the earliest and riskiest stages of businesses.

Since the Fund’s inception, it has made a significant contribution to the commercialisation objectives of its founding partners. The Fund is willing to take risks where there is a lot of uncertainty but also sufficient opportunity to create economic impact and/or public benefit, if successful.

Overall, the risks taken have resulted in a continuing economic value and impact along with wider benefits which can also be seen in some case studies.

Latest News

Neuroprotective Therapy Company Quethera Reveals Gene Therapy Results at ARVO

  Quethera, a biopharmaceutical company developing therapies for ocular disorders, today presented strong efficacy...

read more

Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes

Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total...

read more